Management of Monocytosis

Initial Evaluation

• A thorough patient history focusing on potential reactive causes of monocytosis, including infectious diseases and inflammatory conditions, is essential for diagnosis, according to the European Hematology Association 1
• A complete physical examination with particular attention to spleen size and presence of cutaneous lesions or lymphadenopathy is crucial, as recommended by the American Society of Hematology 2, 3
• Laboratory studies, including complete blood count with differential, peripheral blood smear examination, and blood chemistry, are necessary to assess the patient's condition, as suggested by the International Society for Laboratory Hematology 4, 5, 6

Further Diagnostic Workup

• Bone marrow aspiration and biopsy are recommended if persistent monocytosis is present or hematologic malignancy is suspected, to assess marrow cellularity, presence of dysplasia, and percentage of blasts, according to the World Health Organization 2, 4, 3, 5
• Conventional cytogenetic analysis is necessary to identify clonal abnormalities and rule out Philadelphia chromosome or BCR-ABL1 fusion gene, as recommended by the European LeukemiaNet 4, 3, 5
• Molecular testing, including PCR for BCR-ABL1 fusion gene and testing for mutations commonly found in CMML, may be considered if clinically indicated, as suggested by the National Comprehensive Cancer Network 2, 4

Differential Diagnosis

• Infections, inflammatory conditions, autoimmune disorders, recovery from bone marrow suppression, and solid tumors are potential reactive causes of monocytosis, according to the Infectious Diseases Society of America 1, 3
• Hematologic malignancies, including Acute Myeloid Leukemia and Juvenile Myelomonocytic Leukemia, should be considered in the differential diagnosis, as recommended by the American Society of Clinical Oncology 3, 6

Diagnostic Criteria for CMML

• The World Health Organization 2008 classification requires persistent peripheral blood monocytosis, no Philadelphia chromosome or BCR-ABL1 fusion gene, and less than 20% blasts in peripheral blood and bone marrow, among other criteria, for the diagnosis of CMML, as stated by the WHO 4, 5

Management Approach

• For persistent unexplained monocytosis, bone marrow evaluation and hematology consultation are recommended, according to the European Hematology Association 2, 4, 3, 5
• If CMML is diagnosed, management should be based on risk stratification and may include observation, hypomethylating agents, or allogeneic stem cell transplantation, as suggested by the National Comprehensive Cancer Network 4, 5

Pitfalls to Avoid

• Failing to distinguish between relative and absolute monocytosis, and missing underlying infections or malignancies, can lead to incorrect diagnosis and treatment, as warned by the American Society of Hematology 2, 4, 1

Management of Persistently Elevated Monocytes

Initial Diagnostic Approach

• Evaluation of peripheral blood smear should include assessment of monocyte morphology, presence of dysgranulopoiesis, promonocytes, blasts, and neutrophil precursors 7

Further Diagnostic Workup

• Bone marrow aspiration and biopsy are indicated for persistent unexplained monocytosis to assess percentage of blasts (including myeloblasts, monoblasts, and promonocytes) 8
• Bone marrow biopsy staining should include Gomori's silver impregnation for fibrosis 7
• Conventional cytogenetic analysis is necessary to exclude t(9;22) and t(5;12) translocations 7
• Molecular testing should include testing for molecular mutations commonly found in CMML (e.g., TET2, SRSF2, ASXL1, RAS) 7

Management Based on Diagnosis

For Chronic Myelomonocytic Leukemia (CMML)

• For myelodysplastic-type CMML with <10% bone marrow blasts, implement supportive therapy aimed at correcting cytopenias 8
• For myelodysplastic-type CMML with ≥10% bone marrow blasts, supportive therapy plus 5-azacytidine 8
• For myeloproliferative-type CMML with <10% blasts, cytoreductive therapy with hydroxyurea to control cell proliferation and reduce organomegaly 8
• For myeloproliferative-type CMML with high blast count, polychemotherapy 8
• Allogeneic stem cell transplantation should be considered in selected patients within clinical trials for both myelodysplastic and myeloproliferative CMML 8

Monitoring and Follow-up

• In cases where symptoms improve but biomarkers remain elevated, treatment adjustments may be warranted without need for repeat endoscopic evaluation 9

Common Pitfalls to Avoid

• Not performing comprehensive bone marrow evaluation in cases of persistent unexplained monocytosis 7
• Overlooking the need for molecular testing to exclude specific myeloid neoplasms 7

Differential Diagnosis for Elevated Monocytes

Reactive Causes

• Parasitic infections, including Strongyloides, should be considered, especially with travel history, as a potential cause of monocytosis 10
• Ehrlichiosis (E. chaffeensis, E. ewingii) presents with monocytosis alongside characteristic findings of leukopenia, thrombocytopenia, and elevated hepatic transaminases, according to the Centers for Disease Control and Prevention (CDC) 11

Clonal Causes

• Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase (TK) fusion genes may present with monocytosis on peripheral blood smear, as recommended by the National Comprehensive Cancer Network (NCCN) 10
• Myelodysplastic syndromes (MDS) can present with monocytosis, though absolute monocyte count typically remains <1×10⁹/L, as reported in the journal Blood 12

Diagnostic Evaluation

• Obtain detailed history focusing on travel exposure, new medications, recurrent infections, family history of eosinophilia or hematologic malignancies, and symptoms of immunodeficiency, as recommended by the National Comprehensive Cancer Network (NCCN) 10, 13
• Physical examination must assess spleen size, cutaneous lesions, lymphadenopathy, and signs of organ damage, according to the National Comprehensive Cancer Network (NCCN) 10, 13
• Laboratory studies, including CBC with differential, comprehensive metabolic panel, liver function tests, and peripheral blood smear examination, are essential for diagnosis, as recommended by the National Comprehensive Cancer Network (NCCN) and the journal Blood 10, 13
• Rouleaux formation, which suggests plasma cell dyscrasia, and morulae in monocytes, which suggests ehrlichiosis, are critical morphologic features to evaluate in peripheral blood smear assessment, as reported in the journal Blood and by the CDC 11, 13

Monocytosis Causes and Diagnostic Approach

Reactive Causes of Monocytosis

• Viral infections, including HIV and hepatitis C, can cause monocytosis that may be clinically indistinguishable from primary hematologic disorders, according to the American Society of Hematology 14
• Systemic lupus erythematosus (SLE) and other autoimmune disorders frequently cause monocytosis, as reported by the American College of Rheumatology 14
• Adult-onset Still's disease demonstrates monocytosis as part of its inflammatory profile, as noted by the European League Against Rheumatism 15
• Inflammatory bowel disease and rheumatoid arthritis are associated with elevated monocyte counts, according to the European Respiratory Society 16

Clonal Causes of Monocytosis

• Elevated absolute monocyte count in chronic lymphocytic leukemia (CLL) correlates with inferior outcomes and accelerated disease progression, as reported by the National Comprehensive Cancer Network 17
• Monocyte count is highest in malignant pericardial effusions (79 ± 27%) compared to other causes, according to the European Society of Cardiology 18
• Hypothyroidism shows elevated monocyte percentages in pericardial effusions (74 ± 26%), as noted by the European Society of Cardiology 18

Diagnostic Approach

• The American Society of Hematology recommends a detailed history, physical examination, and complete blood count with differential to determine absolute monocyte count and assess for concurrent cytopenias or other abnormalities 14
• The National Comprehensive Cancer Network suggests that bone marrow aspiration and biopsy are indicated for persistent unexplained monocytosis without clear reactive cause, absolute monocyte count ≥1 × 10⁹/L sustained over time, concurrent cytopenias or other blood count abnormalities, constitutional symptoms or organomegaly, and dysplastic features on peripheral smear 14, 17

Diagnostic Approach to Monocytosis

Initial Laboratory Studies

• The European Society of Medical Oncology recommends a comprehensive metabolic panel including calcium, albumin, and creatinine for patients with monocytosis 19

Additional Testing Based on Clinical Context

• The International Myeloma Society suggests serum protein electrophoresis with immunofixation, serum-free light chains, and 24-hour urine collection for electrophoresis and immunofixation if plasma cell dyscrasia is suspected 20, 19, 21
• The American Society of Hematology recommends CD138 stains if plasma cell dyscrasia is suspected 20

Monocytosis Diagnosis and Thresholds

Diagnostic Criteria

• The World Health Organization recommends an absolute monocyte count >1.0 × 10⁹/L (>1000/μL) in peripheral blood as the diagnostic cutoff for monocytosis, which is the threshold used in the WHO 2008 classification for chronic myelomonocytic leukemia (CMML) 22
• The World Health Organization establishes an absolute monocyte count >1.0 × 10⁹/L as the primary cutoff for defining monocytosis in the context of myeloid neoplasms 22

Clinical Evaluation

• Sustained monocytosis for ≥3 months without evidence of infection, inflammation, or malignancy warrants hematology referral, according to the guidelines based on the Haematologica journal 22

Guideline‑Based Diagnostic Criteria for Myeloid Neoplasms with Monocytosis

Diagnostic Indicators

• The combination of anemia, leukopenia, and an elevated monocyte percentage is indicative of dysplastic bone‑marrow disorders such as myelodysplastic syndromes or chronic myelomonocytic leukemia, according to the NCCN guidelines (2017). 23

Blast‑Percentage Stratification in MDS

• In myelodysplastic syndromes, a bone‑marrow blast proportion of 5–9 % defines the RAEB‑1 subtype, whereas a blast proportion of 10–19 % defines the RAEB‑2 subtype (NCCN 2017). 23

Criteria for Chronic Myelomonocytic Leukemia (CMML)

• A sustained absolute monocyte count ≥1.0 × 10³/µL (≥1000/µL) is required for the diagnosis of CMML (NCCN 2017). 23
• When bone‑marrow blasts are <20 %, absolute monocytes are ≥1.0 × 10³/µL, and the Philadelphia chromosome is absent, the findings support a diagnosis of CMML rather than acute leukemia (NCCN 2017). 23

Overlap Syndromes

• The NCCN recognizes the existence of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes, which may present with features of both disease categories (2017). 23

Monocytosis in Specific Clinical Contexts

Inflammatory Bowel Disease

• In patients with inflammatory bowel disease, the presence of monocytosis is linked to greater disease severity, higher use of steroids and biologic agents, increased need for surgical interventions, and higher overall healthcare utilization, reflecting a poorer long‑term outcome. 24
• Measurement of C‑reactive protein (CRP) is recommended as an inflammatory marker when assessing monocytosis in inflammatory bowel disease patients. 24

Immune Checkpoint Inhibitor Therapy

• In individuals treated with immune checkpoint inhibitors, a transient increase in monocyte count may occur after therapy; this post‑treatment monocytosis is typically not clinically significant and may function as a prognostic rather than a pathological indicator. 25

Hematology Referral

• The emergence of unexplained cytopenias in a patient with monocytosis should prompt referral to a hematology specialist for further diagnostic work‑up. 25

Diagnostic and Therapeutic Guidance for Chronic Myelomonocytic Leukemia (CMML) and Related Myeloid Disorders

Diagnostic Criteria

Peripheral‑Blood Morphology

Bone‑Marrow and Molecular Evaluation

Treatment Strategies

Myelodysplastic‑type CMML (blasts < 10 %)

Myelodysplastic‑type CMML (blasts ≥ 10 %)

Myeloproliferative‑type CMML (blasts < 10 %)

Myeloproliferative‑type CMML (high blast count)

Refractory Disease